ChemoCentryx Inc. (NASDAQ:CCXI) dropped 2.2% on Monday . The stock traded as low as $4.74 and last traded at $4.89, with a volume of 74,188 shares changing hands. The stock had previously closed at $5.00.

A number of research analysts have recently issued reports on CCXI shares. Zacks Investment Research cut shares of ChemoCentryx from a “buy” rating to a “hold” rating in a report on Monday, May 16th. Cowen and Company reiterated a “hold” rating on shares of ChemoCentryx in a report on Thursday, May 19th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating and set a $11.00 price objective on shares of ChemoCentryx in a report on Tuesday, August 9th.

The stock’s 50-day moving average price is $4.59 and its 200 day moving average price is $3.87. The firm’s market capitalization is $234.99 million.

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.